Aggregation and accumulation of amyloid-b peptide (Ab) is a key component of Alzheimer's disease (AD). While monomeric Ab appears to be benign, oligomers adopt a biologically detrimental structure. These soluble structures can be detected in AD brain tissue by antibodies that demonstrate selectivity for aggregated Ab. Protofibrils are a subset of soluble oligomeric Ab species and are described as small (< 100 nm) curvilinear assemblies enriched in b-sheet structure. Our own in vitro studies demonstrate that microglial cells are much more sensitive to soluble Ab42 protofibrils compared to Ab42 monomer or insoluble Ab42 fibrils. Protofibrils interact with microglia, trigger Toll-like receptor signaling, elicit cytokine transcription and expression, and are rapidly taken up by the cells. Because of the importance of this Ab species, we sought to develop an antibody that selectively recognizes protofibrils over other Ab species. Immunization of rabbits with isolated Ab42 protofibrils generated a high-titer anti serum with a strong affinity for Ab42 protofibrils. The antiserum, termed AbSL, was selective for Ab42 protofibrils over Ab42 monomers and Ab42 fibrils. AbSL did not react with amyloid precursor protein and recognized distinct pathological features in AD transgenic mouse brain slices. Competition studies with an Ab antibody that targets residues 1-16 indicated that the conformational epitope for AbSL involved the N-terminal region of protofibrils in some manner. The newly developed antibody may have potential diagnostic and therapeutic uses in AD tissue and patients, and targeting of protofibrils in AD may have beneficial effects.
Amyloid-b peptide (Ab) antibodies have been an important tool in Alzheimer's disease (AD) research (Masters et al. 2016) . Many of the first-line antibodies were instrumental in the detection of pathological Ab hallmarks of the Alzheimer's disease brain including neuritic plaques and cerebral deposits (Wong et al. 1985) . Furthermore, antibodies have allowed quantitative measurement of Ab levels in human fluids (Seubert et al. 1992) . Generation of C-terminal-selective Ab antibodies that distinguish between Ab40 and Ab42 helped resolve the composition of Ab in plaques (Gravina et al. 1995) . More recently, the advent of conformation-selective antibodies has allowed probing of oligomeric and fibrillar structures in vitro, in mouse models, and in human tissues and fluids (Georganopoulou et al. 2005; Kayed et al. 2007; Deshpande et al. 2009; Koffie et al. 2009 ). Increasingly, Ab antibodies are the primary determinant of structural identification for aggregated species found in vivo.
Much of the recent emphasis on soluble Ab aggregates has been on oligomers, yet much more structural information is known about protofibrils. The first observation and characterization of protofibrils 20 years ago described these small soluble species as enriched in b-sheet structure (Walsh et al. 1999) and as precursors to fibrils (Harper et al. 1997; Walsh et al. 1997) . Centrifugation of Ab solutions followed by size exclusion chromatography (SEC) of the supernatant has been instrumental in isolating protofibrils for further characterization (Walsh et al. 1997; Jan et al. 2010) . Previous size analyses of protofibrils yielded lengths of typically < 200 nm (Harper et al. 1997; Walsh et al. 1997 ) and a range of hydrodynamic radii (R H ) values from 10 to 50 nm (Walsh et al. 1997; Paranjape et al. 2012; Nichols et al. 2015) . Structurally, protofibrils have some macroscopic similarities to fibrils based on thioflavin T binding, circular dichroism (Walsh et al. 1999) , and hydrogen exchange (Kheterpal et al. 2003) , but have not yet developed the full stability of fibrillar Ab (Walsh et al. 1999; Kheterpal et al. 2003) . Protofibril diameters are typically smaller than fibrils and range from 4 to 6 nm although the protofibril to fibril transition can occur without a change in diameter via monomer deposition on protofibril ends or end-to-end annealing of protofibrils (Harper et al. 1997 (Harper et al. , 1999 . Protofibril conversion into fibrils can also occur by lateral association of protofibrils (Nichols et al. 2002) . Protofibrils display toxicity to neurons (Walsh et al. 1999) , disrupt ion channels (Ye et al. 2003) , inhibit hippocampal long-term potentiation (O'Nuallain et al. 2010) , and are likely to possess other detrimental biological activities. Protofibrils induce a robust inflammatory response (Paranjape et al. 2012 (Paranjape et al. , 2013 , initiate Toll-like receptor signaling (Terrill-Usery et al. 2014) , and are preferentially internalized by microglia (Gouwens et al. 2016) . Their solubility and diffusible nature quite possibly render them more effective in cellular interactions and engaging microglial receptors compared to mature insoluble fibrils.
Because of the potential role of Ab42 protofibrils in AD and the ability of these soluble and diffusible protein aggregates to directly impact neuronal viability and stimulate microglial activation, we sought to develop an antibody that selectively recognizes protofibrils. The current report details the generation and characterization of an anti-protofibril serum antibody termed antibody St. Louis (AbSL). 
Materials

Resource identifiers
Methods
Preparation of Ab peptides
Ab42 and Ab40 peptides were obtained from The ERI Amyloid Laboratory, LLC (Oxford, CT, USA) in lyophilized form and stored at À20°C. Ab peptide was dissolved in 100% hexafluoroisopropanol (Sigma-Aldrich, St. Louis, MO, USA) to yield a 1 mmol/L Ab solution, separated into aliquots in sterile microcentrifuge tubes, and evaporated uncovered at 25°C overnight in a fume hood. The following day the aliquots were vacuum-centrifuged to remove any residual hexafluoroisopropanol and stored in desiccant at À20°C. Ab42 protofibrils were prepared as previously described (Paranjape et al. 2012) by dissolving lyophilized Ab (2 mg) in 50 mmol/L NaOH to yield a 2.5 mmol/L Ab solution. The solution was then diluted to 250 lmol/L Ab in pre-filtered (0.22 lmol/L) artificial cerebrospinal fluid (aCSF, 15 mmol/L NaHCO 3 , 1 mmol/L Na 2 HPO 4 , 130 mmol/L NaCl, 3 mmol/L KCl, pH 7.8), incubated for 15-30 min at 25°C, and centrifuged at 18 000 g for 10 min with a Beckman-Coulter Microfuge 18 prior to chromatographic analysis of the supernatant. Ab40 protofibrils were prepared in a similar manner although the Ab40 solution concentration was 500 lmol/L and the solution was incubated for 72 h at 37°C. Protofibril preparations also yielded almost 50% Ab42 monomers for further use. Alternatively, aliquots of Ab42 were reconstituted in 6 mol/L guanidine hydrochloride/10 mmol/L NH 4 OH to discourage protofibril formation and increase the yield of monomers for subsequent SEC purification. Ab25-35 (0.5 mg) was reconstituted using the guanidine hydrochloride method and Ab25-35 monomers were isolated in aCSF. Ab42 fibrils were prepared from purified Ab42 monomers by incubation in low retention (siliconized) tubes for 360 h at 4°C. Fibril formation was confirmed with thioflavin T fluorescence and sedimentation by centrifugation at 18 000 g. Aggregation of Ab25-35 (130 lmol/L) was accomplished by shaking a solution of purified Ab25-35 monomers in a low retention tube on an IKA shaker at 750 rpm for 6 days at 25°C.
Size exclusion chromatography
Supernatants of Ab preparations (protofibrillar or monomer) were fractionated on a Superdex 75 HR 10/30 column (GE Healthcare, Pittsburgh, PA, USA) with a fractionation range of 3-70 kD using an AKTA FPLC system (GE Healthcare). Prior to chromatographic isolation of Ab, bovine serum albumin (BSA, 5 mg) taken from a sterile 75 g/L fraction V solution (Sigma, St Louis, MO, USA) was passed over the column to limit non-specific binding of Ab to the column matrix. Following sample loading, Ab was eluted at 0.5 mL/min in aCSF and 0.5 mL fractions were collected and immediately placed on ice. Ab42 and Ab40 concentrations were determined by in-line UV absorbance using an extinction coefficient of 1450/cm M at 280 nm. Ab25-35 concentration was determined by bicinchoninic acid assay using BSA to construct a standard curve.
Dynamic light scattering
Hydrodynamic radius (R H ) measurements were made at 25°C with a DynaPro Titan instrument (Wyatt Technology, Santa Barbara, CA, USA). Samples (35 lL) were placed directly into a quartz cuvette and light scattering intensity was collected at a 90°angle using a 5-s acquisition time. Particle diffusion coefficients were calculated from autocorrelated light intensity data and converted to R H with the Stokes-Einstein equation. Mean R H values were obtained with Dynamics software, Wyatt Technology, Santa Barbara, CA, USA (version 6.12.03).
Thioflavin T fluorescence Ab solutions were assessed by thioflavin T (ThT) fluorescence as described previously (Nichols et al. 2002) . SEC Ab fractions were diluted in aCSF pH 7.8 containing 10 lmol/L ThT. Fluorescence emission scans (460-520 nm) were acquired on a Cary Eclipse fluorescence spectrophotometer using an excitation wavelength of 450 nm. Emission scans were integrated from 470 to 500 nm to provide a numerical value of ThT relative fluorescence values.
Electron microscopy SEC-purified Ab42 protofibrils and Ab25-35 aggregates (10 lL) were applied to a 200-mesh formvar-coated copper grid (Ted Pella, Inc., Redding, CA, USA). Samples were allowed to adsorb for 10 min at 25°C, followed by removal of excess sample solution. 
Dot blot
Dilutions of Ab42 protofibrils, fibrils, and monomers (2 lL) were applied to a pre-wetted and dried nitrocellulose membrane and allowed to dry for 20 min. The membrane was incubated in blocking buffer (PBST containing 0.1 g/mL milk) on a rotary shaker for 1 h. After washing the membrane for 5 min 39 with PBST, the membrane was incubated with AbSL (1 : 1000 dilution) under gentle rotation (70 rpm) for 1 h. A second wash step was followed by a 1 : 1000 dilution of antirabbit IgG-HRP antibody for 1 h and a third wash step. The membrane was then treated with Pierce enhanced chemiluminescence western blotting substrate for 1 min under vigorous rotation (120 rpm). Biomax XAR film (Millipore Sigma, St. Louis, MO, USA) was exposed to the membrane and developed.
Western Blot
All animal use was approved by the University of North Dakota Institutional Animal Care and Use Committee (1505-3). Temporal cortex from C57BL/6 (WT), APP À/À , and APP/PS1 [(APPswe, PSEN1dE9)85Dbo/Mjax] mice (Jackson Laboratory) was homogenized in a radioimmunoprecipitation assay buffer containing protease inhibitor (Sigma Aldrich P8340) and sodium orthovanadate as a phosphatase inhibitor. The concentration of each protein homogenate was determined using the Bradford method (Bradford 1976) . A quantity of 10lg of each protein sample was then resolved by 0.1 g/ mL sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Proteins were then transferred to polyvinylidene difluoride membrane and blocked using a 0.05 g/mL BSA solution for 1 h before application of primary antibody diluted in 0.05 g/mL BSA. Antibodies against full-length c-terminal APP (Y188; Abcam) (22C11; Millipore), Ab (4G8; Biolegend), human APP/Ab (6E10; Biolegend), and GAPDH (6C5; Santa Cruz Biotechnology) as a loading control were applied at a 1 : 1000 dilution overnight at 4°C. AbSL antiserum was utilized at a 1 : 5000 dilution in a 0.05 g/mL milk solution overnight at 4°C. Species-specific HRP-conjugated secondary antibodies were applied to blots for 2 h, then blots were washed with Trisbuffered saline containing 1 mL/L Tween 20 (TBS-T). Blots were visualized using chemiluminescence and images were acquired using an Omega™ Lum G imaging system (Gel Company, San Francisco, CA, USA).
Brain Immunofluorescence
Fifteen-month-old WT (C57BL/6) or APP/PS1 female animals were killed and perfused using sterile Ca 2+ /PBS solution. Brain hemispheres were collected and chemically crosslinked (fixed) for 24 h in 4% paraformaldehyde/PBS solution. After 24 h of fixation, brain hemispheres were then equilibrated three times over 3 days in 0.15 g/mL (15%), 0.3 g/mL (30%) and 0.3 g/mL (30%) sucrose-PBS solutions until flotation ceased. Brain hemispheres were then embedded in 0.15 g/mL gelatin and sliced to a thickness of 40 microns using a sliding microtome (Leica, Wetzlar, Germany). Antigen retrieval was performed on brain sections prior to immunostaining by applying 0.25 g/mL formic acid solution to brain sections for 25 min at 25°C. Immunoflourescent labeling of free-floating brain sections was performed using the 4G8 antibody and AbSL antiserum at a 1 : 500 dilution in immunostain solution (PBS containing 0.005 g/mL BSA, 1 mL/L Triton X-100, 50 mL/L horse serum, and 0.2 g/L sodium azide). Tissue sections were treated with antibodies in solution for 48 h with gentle mechanical agitation. Sections were then washed with immunostain solution and incubated with AlexaFluor 488-anti-rabbit or AlexaFluor 594-anti-mouse secondary antibodies (ThermoFisher Scientific Waltham, MA, USA) for 4 h at a 1 : 2000 dilution. Non-specific secondary antibody staining was determined using secondary antibodies alone without primary antibodies. Following secondary antibody application, tissue was washed two times with immunostain solution and then two times in PBS alone before mounting on glass slides. Tissue was allowed to briefly dry and adhere to slides for 30 min with continuous air flow before application of ProLong Diamond antifade mounting media with 4 0 ,6-diamidino-2-phenylindole(DAPI) (ThermoFisher Scientific) and coverslips. Sections were visualized using a Leica DMI600B epiflourescent microscope or a Zeiss (Oberkochen, Germany) LSM 510 meta confocal microscope using a 488 nm or 543 nm laser to excite flourophores. Epiflourescent images were compiled as TIFFs for production of figures, while confocal.lsm files were converted to TIFF files using ImageJ software (Open source, PMID 22930834) with final figures produced using Photoshop software, Adobe, San Jose, CA, USA.
Sandwich ELISA A quantity of 0.1 mL capture antibodies in PBS (Ab9, 1 lg/mL; Ab2.1.3, 5 lg/mL) were added to wells of a 96-well immunoplate, incubated overnight, washed with PBST, and blocked the next day with 0.3 mL PBST containing 0.1 g/mL milk for 1 h. PBST washes (93) were done in between each of the following steps. Ab42 protofibrils (50 lL) in aCSF were incubated on the capture antibodies for 2 h, the plate was washed, followed by addition of 0.1 mL of HRP-conjugated or unlabeled detection antibody diluted in PBST containing 0.05 g/mL milk for 2 h. When unlabeled AbSL was used as the primary detection antibody, a secondary HRPlabeled anti-rabbit IgG detection antibody (0.1 mL) was added for an additional 2 h. After a final wash step, 0.1 mL of 3,3 0 ,5,5 0 -tetramethylbenzidine substrate was added for 2-5 min prior to stopping the reaction with 0.05 mL 1 mol/L sulfuric acid. Absorbance was obtained as described for the indirect ELISA.
Statistical analysis
Data points are presented as mean AE standard error measurement (SEM). Values statistically different from controls were determined using an one-way ANOVA when applicable.
Results
Characterization of Ab42 protofibrils and immunization
Ab42 protofibrils were prepared and isolated by SEC (Fig. 1a) in a modified aCSF buffering system as previously detailed (Paranjape et al. 2013) . Sufficient amounts (2 mL, 0.2 mg/mL) of protofibrils were obtained and characterized prior to rabbit immunization. Ab42 protofibrils, which we have previously determined to range in molecular weight from 200 to 2600 kD (Nichols et al. 2015) , eluted in the void volume of a Superdex 75 column. These fractions bound thioflavin T (ThT), resulting in a marked increase in 480 nm fluorescence emission (Fig. 1b) . Protofibrils from the peak SEC fractions were pooled and analyzed by transmission electron microscopy (TEM). Short (< 100 nm), curvilinear structures were observed (Fig. 1c) . The size of the protofibrillar species was consistent with earlier dynamic light scattering examinations with a mean hydrodynamic radius (R H ) of 18.0 AE 2.5 nm (standard deviation) (Fig. 1d ). Preimmune serum was obtained from two rabbits that were subsequently immunized (Pacific Immunology, CA) with Ab42 protofibrils once in Complete (CFA) and twice in Incomplete Freund's Adjuvant over a 6-week period. Two bleeds were obtained over 3 weeks followed by a third immunization in Incomplete Freund's Adjuvant and two additional bleeds.
Titer determination of antiserum and selectivity for Ab species The pre-immune serum (PB) and all four bleeds (B1-4) from both rabbits were evaluated for Ab recognition using an indirect ELISA assay as outlined and depicted in Fig. 8(a) . Ab42 protofibrils were adsorbed to the wells of a 96-well immunoplate overnight and exposed to increasing dilutions of the rabbit serum. Rabbit #1 (PAC79) displayed high titers for protofibrils within the first bleed and the antibody titer level remained consistent throughout the bleed protocol (Fig. 2a) . Rabbit #2 (PAC80) was slower to generate antibodies but eventually displayed antibody titers that matched and exceeded those of Rabbit #1 (Fig. 2b) . Antibody titers were determined to range from 25 000 to > 50 000 in the newly characterized antiserum, denoted AbSL antiserum. Serum AbSL titers were also tested against different forms of Ab42, including protofibrils, monomers, and fibrils (Fig. 2c) . Curve-fitting with a 3-parameter hyperbolic decay produced EC 50 serum dilution values of 1 : 542, 1 : 14, and 1 : 84 for protofibrils, monomers, and fibrils, respectively. The selectivity for Ab42 protofibrils by AbSL antiserum was further tested by adsorbing isolated Ab42 protofibrils, monomers, and fibrils at similar concentration ranges to immunoplates and carrying out an indirect ELISA. Significant selectivity was observed by AbSL antiserum for protofibrils compared to monomers and fibrils at lower mass amounts of Ab42 (Fig. 3a) . Extended concentration ranges of the three Ab42 species (Fig. 3b) highlighted the selectivity both in the magnitude and EC 50 of the response (protofibrils, 59 ng; monomers, 124 ng; fibrils, 2845 ng). A semi-log plot of the extended Ab concentration data in Fig. 3(b) was used to better emphasize the selectivity differences in AbSL for distinct Ab42 species (Fig. 3c) .
Under the same conditions, Ab9, a monoclonal Ab antibody (IgG2a isotype) of mouse origin that recognizes the peptide N-terminal domain (residues 1-16) and is not conformation-selective (Kukar et al. 2005; Levites et al. 2006) , did not display any selectivity between protofibrils and monomers (Fig. 3d) . Reactivity to fibrils by Ab9 was decreased somewhat, although not nearly to the same extent as AbSL antiserum. The lower reactivity to fibrils by Ab9 may reflect coverage of some epitopes by the fibril macrostructure (i.e., lateral association of filaments) and is likely not representative of conformational selectivity.
We have previously shown that Ab40 protofibrils take longer to form, are less stable, and exhibit a reduced ability to induce tumor necrosis factor alpha (TNFa) secretion in microglia than Ab42 protofibrils (Paranjape et al. 2012) . Indirect ELISA analysis of AbSL antiserum reactivity to immunoplate-adsorbed Ab42 or Ab40 protofibrils suggested a higher affinity for Ab42 protofibrils (Fig. 3e) . Curve-fitting with a single rectangular hyperbola equation yielded a value for the amount of Ab adsorbed at half-maximal binding of 4 ng for Ab42 protofibrils and 16 ng for Ab40 protofibrils. Dot blot analysis also demonstrated the selective affinity of AbSL for Ab42 protofibrils over Ab42 monomers (Fig. 4a) and fibrils (Fig. 4b) . Ab9 was again used as a positive control in Fig. 4(a) to confirm the presence of Ab42 monomers on the nitrocellulose membrane.
AbSL does not recognize APP An important criterion for antibodies that are designed to be specific for Ab is that they do not bind the APP. APP is an integral membrane protein that yields Ab after proteolytic cleavage by b and c secretases (Hardy and Selkoe 2002) . Since the Ab sequence is within APP, there can sometimes be cross-reactivity by antibodies for Ab and APP. A major band for APP is typically observed around 100-130 kD (Selkoe et al. 1988) . The temporal cortices of C57BL/6 wildtype (WT), APP knockout (APP À/À ), and mutant APP/ presenilin (APP/PS1) mice were collected and homogenized to yield protein extracts (Zheng et al. 1995; Jankowsky et al. 2004) . Protein homogenates were analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis/immunoblot to determine reactivity to APP (~110 kD). Membranes were probed with AbSL, anti-APP (C2211 and Y188), anti-Ab (4G8 and 6E10), and anti-GAPDH antibodies. Robust antibody binding around 110 kD was detected on membranes probed with the 22C11 and Y188 antibodies in with Ab42 protofibrils, Ab42 monomers, and Ab42 fibrils were treated with the N-terminal Ab antibody Ab9 (1 : 5000 dilution) and anti-mouse IgG-HRP. (e) Ab42 protofibrils and Ab40 protofibrils were prepared separately by different protocols and isolated by size exclusion chromatography. 96-well ELISA plates were coated with a concentration range of protofibrils (0.9-18 ng per well) and analyzed by indirect ELISA. Wells were incubated with AbSL (1 : 1000 dilution) followed by anti-rabbit IgG-HRP secondary antibody. Curve-fitting of the data points was performed using SigmaPlot software. Error bars depict SEM for n = 3 wells.
WT and APP/PS1 temporal cortex samples, and was absent in APP À/À samples (Fig. 5a ) supporting their selectivity for APP. The 6E10 monoclonal antibody, which is known to be preferentially selective for human APP, reacted with the human transgenic APP in the APP/PS1 cortex lysate and did not detect mouse APP in WT samples or show binding in APP À/À samples. Full-length APP in WT and APP/PS1 cortex homogenates was not detected by the 4G8 antibody. AbSL did not react with the 110 kD band over background (Fig. 5a ). Similar results were obtained in an additional gel and immunoblotting experiment that also contained an in vitro-prepared soluble oligomeric/protofibrillar Ab42. 22C11 recognized full-length APP, but not the Ab42 species (Fig. 5b) as predicted based upon its N-terminal APP epitope. AbSL recognized the Ab42 species, but not APP. Taken together, these findings indicate that AbSL antiserum is Ab conformation-selective with little to no APP cross-reactivity.
AbSL recognizes distinct pathological features in APP/PS1 brain tissue
Brain slices from 15-month-old APP/PS1 mice were stained with AbSL antiserum and 4G8 monoclonal antibody. 4G8 is reactive to residues 17-24 of aggregated and unaggregated Ab (Kim et al. 1988) . Confocal imaging of the brain tissue showed classical plaque-like features that were recognized by both AbSL and 4G8 (Fig. 6a) . However, significant differences were observed in the response and localization of each antibody. Notably distinct areas were stained by one antibody or the other without colocalization. In many cases, AbSL stained fringe areas of the amyloid plaque and had a strong reactivity overall. There were a number of areas that did indicate colocalization by AbSL and 4G8. The confocal microscopy findings in Fig. 6 (a) suggested that there were areas of Ab structure in the pathology that were uniquely accessible by AbSL. Epifluorescence imaging of hippocampal slices obtained from 15-month-old APP/PS1 mice ( Fig. 6b ) revealed numerous accumulations that were detected by AbSL but not 4G8. The number and intensity of the accumulations was substantial. The pathology was not observed in 15-month-old WT mice (Fig. 6c ). Both types of fluorescence imaging highlighted the robust staining capability of AbSL.
Epitope competition between AbSL and other Ab antibodies
The analysis provided strong evidence for AbSL recognition of a conformational epitope present on Ab42 protofibrils. In order to gain further information on the AbSL epitope on protofibrils, AbSL binding was assessed by indirect ELISA competition studies with Ab9 (anti-Ab 1-16 mAb of IgG2a isotype) or Ab5 (anti-Ab 1-16 mAb of IgG2b isotype). Ab9 and Ab5 are from the same antibody lineage and have the same epitope. Ab42 protofibrils were coated onto an immunoplate followed by application of antibody mixtures containing AbSL (at a fixed dilution) and Ab9 (increasing concentration). The binding of AbSL was monitored by an anti-rabbit IgG-HRP secondary antibody. The data showed that increasing amounts of Ab9 blocked AbSL binding to protofibrils up to a certain point and then had no additional effect (Fig. 7a, circles) . Application of Ab9 alone to the protofibrils at the same concentrations served as a control measurement and was detected by an anti-mouse IgG-HRP secondary antibody (Fig. 7a, diamonds) . Ab9 alone was undetectable by the anti-rabbit IgG-HRP secondary antibody (Fig. 7a, triangles) demonstrating that the anti-rabbit IgG-HRP secondary antibody only monitored AbSL binding to the protofibrils.
Reverse competition experiments were also conducted in which premixed primary antibody solutions contained varied AbSL dilutions with a fixed Ab5 concentration. Multiple experiments at different fixed Ab5 concentrations indicated that an increase in the Ab5 concentration affected AbSL/ Ab42 protofibril binding (Fig. 7b) . Curve-fitting with a 3-parameter single rectangular hyperbola produced EC 50 serum dilution values of 1 : 620 for AbSL alone, 1 : 534 for AbSL + 1 : 10 000 Ab5, 1 : 247 for AbSL + 1 : 2000 Ab5, and 1 : 151 for AbSL + 1 : 1000 Ab5 (Fig. 7b) . Thus, increased Ab5 concentration lowered the response and the affinity of AbSL for Ab42 protofibrils. However, the effect was finite and leveled out at fixed Ab5 dilutions less than 1 : 2000. In a separate experiment, a mouse IgG2a isotype control antibody for Ab5 used at the highest Ab5 concentration (1 : 1000, 1.4 lg/mL) had no effect on AbSL affinity for Ab42 protofibrils (data not shown). The competition findings indicated that the AbSL conformational epitope and the Ab9/Ab5 linear sequence epitope were distinct but with some potential regions of overlap.
The possibility that the AbSL conformational epitope on Ab42 protofibrils may involve the N-terminal region of the peptide was further probed by direct and indirect sandwich ELISA (Fig. 8a) . Ab antibodies Ab9 (or Ab5) and Ab2.1.3, a C-terminal Ab42-selective antibody (Kukar et al. 2005) , were used as capture antibodies for Ab42 protofibrils in the sandwich ELISA. The capture antibodies were tested in combination with detection antibody Ab5 conjugated to HRP (Ab5-HRP) in a direct sandwich ELISA or detection antibody AbSL and anti-rabbit IgG-HRP in an indirect sandwich ELISA (Fig. 8a) . The combination of the Ab42 C-terminalselective antibody Ab2.1.3 to capture the protofibrils and the N-terminal-selective Ab5-HRP to detect the protofibrils produced a final ELISA absorbance (OD 450 nm ) well above background (Fig. 8b) . Capture with Ab2.1.3 and detection with AbSL also yielded a significant OD 450 nm above background levels. This finding suggested that the protofibril epitope for AbSL did not overlap with the C-terminal end of Ab42. Capture with Ab9 and detection with Ab5-HRP yielded a negligible OD 450 nm , consistent with both antibodies recognizing and competing for the same epitope. Capture with Ab9 and detection with AbSL, although, produced a significant OD 450 nm signal relative to background. This result indicated that while indications of overlap were noted, there were distinctions between the two antibody binding sites. The partial overlap between the N-terminal Ab9 epitope and the AbSL conformational protofibril epitope was again observed with the Ab9/AbSL OD 450 nm less than that of Ab2.1.3/AbSL (Fig. 8b) . However, when varying the AbSL detection antibody dilution after capture of Ab42 protofibrils by either C-terminal Ab2.1.3 or N-terminal Ab5, the response curves appeared similar (Fig. 8c) . Curve-fitting indicated the Ab5/AbSL combination to be more sensitive with an EC 50 at a greater dilution (1 : 1581) compared to the Ab2.1.3/AbSL combination (1 : 473). Overall, competition between AbSL and N-terminal antibodies Ab9/Ab5 for Ab42 protofibrils was less evident in the sandwich ELISA compared to the indirect ELISA.
Ab42 protofibril standard curves were examined using an indirect sandwich ELISA format to further distinguish the AbSL conformational epitope from the sequence-dependent N-terminal Ab9 epitope. A characteristic binding curve was observed over a concentration range of Ab42 protofibrils when immunoplates were coated with the Ab42 C-terminalselective antibody Ab2.1.3 (capture antibody) followed by AbSL (detection antibody) and anti-rabbit IgG-HRP (Fig. 9a) . Although the A 450 nm was diminished when Ab9 was used as the capture antibody, the shape and sensitivity of the AbSL binding curve to protofibrils was similar to Ab2.1.3 (Fig. 9b) . Curve-fitting confirmed this observation with EC 50 values of 3.5 ng Ab and 2.4 ng Ab for capture antibodies Ab2.1.3 and Ab9, respectively. The findings were indicative of a conformationally distinct site for AbSL that may involve the N-terminal Ab domain. The sandwich ELISA findings also emphasized the capability of AbSL as a sensitive detection antibody.
Additional analysis utilized an Ab peptide fragment, Ab25-35, which contains only the hydrophobic C-terminal region of Ab. SEC-purified monomers were aggregated under vigorous shaking conditions and displayed ThT fluorescence after 6 days (Fig. 10a) . The ThT-positive material was sedimented by centrifugation of the solution at 18 000 g. The Ab25-35 fibril pellet was isolated and analyzed by TEM (Fig. 10b) . Thick bundles of relatively short (200-400 nm) rod-like structures were observed. However, neither Ab25-35 fibrils, nor Ab25-35 monomers were detected by AbSL antiserum (Fig. 10c) . The Ab25-35 fibrils and monomers were also not detected by the N-terminal Ab9 antibody (data not shown). These findings demonstrated that ThT binding or fibril formation was not completely sufficient for AbSL recognition and that Ab protofibrils possess a particular distinct conformation that appears to involve the Ab N-terminal region in some manner. The absence of N-terminal and C-terminal Ab segments within Ab25-35 may also contribute to the lack of recognition by AbSL.
Discussion
This report describes a new serum antibody that is selective for Ab42 protofibrils and provides further information on the organization of the protofibril epitope. There are numerous antibodies that are reported to be selective for soluble Ab aggregates. The antibody that is most similar to AbSL is mAb158, a protofibril-specific monoclonal IgG2a antibody generated by immunization of mice with protofibrils prepared from Ab42 E22G (Arctic mutation) (Englund et al. 2007) . As with AbSL antiserum, selectivity was observed for mAb158 between protofibrils and monomers. BAN2401 is a humanized IgG1 version of mAb158, has the same binding characteristics as mAb158 (Lannfelt et al. 2014) , and is currently in clinical trials as a potential AD therapeutic (Logovinsky et al. 2016) . The Ab42 Arctic protofibrils in the mAb158 study (Englund et al. 2007 ) appear larger than Immunoplates were coated with Ab protofibrils (18 ng/well) and treated with premixed primary antibody solutions. These solutions contained increasing dilutions of AbSL (100, 500, 1000, 2000, 5000, 10 000, and 20 000) either in the absence (blue circles) or presence of constant amounts of Ab5. Repeated experiments were done at constant Ab5 dilutions of 1 : 10 000 (green triangles), 1 : 2000 (dark red squares), and 1 : 1000 (red diamonds). Each experiment determined AbSL binding in the absence of Ab5. Data points (AE SEM) represent the average of n = 3 trials for each Ab5 dilution and n = 12 trials for AbSL alone. Antibody binding on the y-axis is presented as percent A 450 of the highest AbSL concentration (1 : 100) in the absence of Ab5. . ELISA plates were coated with capture antibodies Ab2.1.3 (5 lg/mL) and Ab9 (1 lg/mL) for the indirect sandwich ELISA, which was carried out as described in the Methods. Ab42 protofibrils (18 ng/well) were added to the capture antibodies followed by various detection antibodies. Background controls (no Ab42) are shown in the black bars while Ab42 samples are shown in white bars. Sample data are the mean of n = 4 replicates AE SEM. (c) Immunoplates were coated with capture antibodies Ab2.1.3 or Ab5 as described in (b). Ab42 protofibrils (45 ng/well) were added and detected with varying dilutions of AbSL (100-20 000). Sample data are the mean of n = 3 replicates AE SEM and were fit to a 3-parameter single rectangular hyperbola equation. Fig. 8(a) , increasing amounts of Ab42 were added to immunoplates previously coated with primary antibodies Ab2.1.3 (a) or Ab9 (b). Detection was accomplished with AbSL antiserum followed by an antirabbit IgG-horseradish peroxidase secondary detection antibody. Sample data points are the mean of n = 3 replicates AE SEM and demonstrate a similar affinity of AbSL for protofibrils even in the presence of Ab9. those prepared from WT Ab42 both in that report and the protofibrils used here in the current study for AbSL generation (Fig. 1) . This may explain the observed selectivity by AbSL for protofibrils over fibrils while mAb158 was less able to distinguish between the two Ab species. Although there is likely to be high structural similarity between protofibrils prepared in different laboratories, there are also possibilities for subtle differences between preparations and somewhat different antibody properties. Therefore, it is expected that there may be differences in affinity and binding sites between similar Ab conformational-selective antibodies.
A well-recognized conformational-specific antibody that targets oligomers of Ab and other amyloid proteins is A11 (Kayed et al. 2003) . A11 displays significant selectivity for oligomers over both monomeric and fibrillar Ab. However, little structural information is known about oligomers and thus the conformational epitope for A11 has not been fully elucidated. Even to this day, biophysical analyses have yet to completely resolve all the structural similarities and differences between soluble oligomers and protofibrils. A11 has been used to detect oligomers in brain tissue from AD mouse models (Lesne et al. 2006; Deshpande et al. 2009 ).
NAB61 is a monoclonal antibody that preferentially recognizes a conformational epitope present in dimeric, small oligomeric, and higher order Ab structures including plaques in human AD brain tissue (Lee et al. 2006) . NAB61 was an important component in determining that senile plaques in an AD mouse model were surrounded by a halo of oligomeric Ab (Koffie et al. 2009 ).
M93 and M94 antibodies were obtained from rabbits immunized with solutions of Ab-derived diffusible ligands (ADDLs), an oligomeric form of Ab (Lambert et al. 2001) . The two polyclonal antibodies were conformational-selective in that they bound Ab42 ADDLs with a much higher affinity than Ab42 monomers. M93 and M94 also bound higher order Ab species including amyloid fibrils. M93 detected an oligomeric species similar to ADDLs in human AD brain extracts (Lambert et al. 2001) . Interestingly, solanezumab (m266), another conformation-selective Ab antibody, binds effectively to oligomeric Ab and has high affinity for monomeric Ab, but does not bind fibrils (reviewed in Goure et al. 2014) .
Several published reports have demonstrated the involvement of the Ab N-terminal region in the recognition of Ab by conformational-selective antibodies. Meli et al. (2009) generated anti-Ab recombinant single chain Fv fragment (scFv) antibodies with a high affinity for Ab oligomers compared to Ab monomers that also had a preference for the N-terminus or C-terminus. The Ab epitope for monoclonal antibody PFA1 comprises N-terminal residues 3-6, yet the antibody has a higher affinity for Ab fibrils and protofibrils than for monomers (Gardberg et al. 2007 (Gardberg et al. , 2009 ). This finding suggested that a combination of conformation and sequence elements involving the Ab N-terminal region were integral in antibody recognition. A thorough analysis of 23 monoclonal conformationally selective OC antibodies by Glabe and coworkers found that 17 of the antibodies recognize a linear segment in the Ab N-terminus (Hatami et al. 2014) . These studies, and the current work with AbSL, indicate that there may be some sort of structural framework within the N-terminal region, which was previously thought to be conformationally flexible. The findings from this report on AbSL suggest a partial overlap between the Ab42 protofibril conformational epitope and the Ab42 N-terminal sequence.
AbSL, an Ab42 protofibril-selective antiserum, shows promise as a tool for detecting, targeting and regulating Ab protofibrils. Serum antibodies have limitations, thus affinity purification and monoclonal development of AbSL antibodies may increase effectiveness and selectivity. Conformationspecific antibodies in AD have research, diagnostic, and therapeutic applicability. They are currently the best option for analyzing human and mouse model samples and, in some cases, may confirm the physiological existence of particular Ab forms or structures. There are a number of antibodybased immunotherapies targeting Ab currently in clinical trials ) and this strategy may be improved by antibodies that are selective for a particular Ab conformation.
